KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Short term Debt: 2011-2024

Historic Short term Debt for Supernus Pharmaceuticals (SUPN) over the last 7 years, with Dec 2024 value amounting to $47.3 million.

  • Supernus Pharmaceuticals' Short term Debt fell 75.88% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year decrease of 75.88%. This contributed to the annual value of $47.3 million for FY2024, which is 9.08% down from last year.
  • Supernus Pharmaceuticals' Short term Debt amounted to $47.3 million in FY2024, which was down 9.08% from $52.1 million recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Short term Debt peaked at $52.1 million during FY2023, and registered a low of $21.1 million during FY2022.
  • Over the past 3 years, Supernus Pharmaceuticals' median Short term Debt value was $47.3 million (recorded in 2024), while the average stood at $40.2 million.
  • In the last 5 years, Supernus Pharmaceuticals' Short term Debt slumped by 52.90% in 2022 and then soared by 146.54% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Short term Debt (Yearly) stood at $30.9 million in 2020, then soared by 45.11% to $44.8 million in 2021, then crashed by 52.90% to $21.1 million in 2022, then skyrocketed by 146.54% to $52.1 million in 2023, then declined by 9.08% to $47.3 million in 2024.